Journal Article

Targeted disruption of the synovial sarcoma-associated <i>SS18</i> gene causes early embryonic lethality and affects <i>PPARBP</i> expression

D.R.H. de Bruijn, W.J.M. Peters, S.M. Chuva de Sousa Lopes, A.H.A. van Dijk, M.P. Willemse, R. Pfundt, P. de Boer and A. Geurts van Kessel

in Human Molecular Genetics

Volume 15, issue 19, pages 2936-2944
Published in print October 2006 | ISSN: 0964-6906
Published online August 2006 | e-ISSN: 1460-2083 | DOI:
Targeted disruption of the synovial sarcoma-associated SS18 gene causes early embryonic lethality and affects PPARBP expression

Show Summary Details


The synovial sarcoma-associated protein SS18 (also known as SYT or SSXT) is thought to act as a transcriptional co-activator. This activity appears to be mediated through the SWI/SNF proteins BRG1 and INI1 and the histone acetyl transferase p300. Here, we report that disruption of the mouse Ss18 gene results in a recessive embryonic lethal phenotype, due to placental failure caused by impairment of placental vascularization and/or chorio-allantoic fusion. This phenotype resembles the p300 knockout phenotype, but is distinct from the Brg1 and Ini1 knockout phenotypes. Through expression profiling of knockout embryos, we observed altered expression of genes known to affect placental development, including the peroxisome proliferator-activated receptor-binding protein (Pparbp). Since Pparbp null mutant embryos display a similar, lethal phenotype with placental failure, we suggest that the functional and phenotypic co-linearities between Ss18 and p300 may also include the transcriptional co-activator Pparbp. Additional interbreeding of Ss18 and Ss18l1 (Crest) mutant mice indicates that these two functionally and structurally related genes may act synergistically during critical stages of embryonic development.

Journal Article.  5557 words.  Illustrated.

Subjects: Genetics and Genomics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.